Prostate Cancer - Results from #23300

Life expectancy estimates as a key factor in over-treatment: The case of prostate cancer - Abstract June 6, 2013

Prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer death - Abstract June 6, 2013

Radical prostatectomy versus high dose permanent prostate brachytherapy using iodine-125 seeds for patients with high risk prostate cancer: A matched cohort analysis - Abstract June 6, 2013

Vesicocutaneous fistula following adjuvant radiotherapy for prostate cancer - Abstract June 6, 2013

Gleason score 7 adenocarcinoma of the prostate with lymph node metastases: Analysis of 184 radical prostatectomy specimens - Abstract June 6, 2013

ASCO 2013 - Poster: Evolving patterns of metastatic disease in castration-resistant prostate cancer (CRPC) reported in clinical trials from 1990 to 2011 June 6, 2013

Prostate brachytherapy: Indications and outcomes - Abstract June 6, 2013

Intermittent androgen-deprivation therapy in prostate cancer: A critical review focused on phase 3 trials - Abstract June 6, 2013

The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: A systematic review and meta-analysis - Abstract June 6, 2013

ASCO 2013 - Poster: Novel predictive markers of PSA response to abiraterone acetate in men with metastatic castration-resistant prostate cancer (mCRPC) June 6, 2013

ASCO 2013 - Podcast: Novel predictive markers of PSA response to abiraterone acetate in men with metastatic castration-resistant prostate cancer (mCRPC) June 6, 2013

ASCO 2013 - Poster: Efficacy and safety of radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel in the phase 3 ALSYMPCA trial June 6, 2013

ASCO 2013 - Podcast: Efficacy and safety of radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel in the phase 3 ALSYMPCA trial June 6, 2013

AUA 2013 - Cancer immunotherapy: Fundamental concepts and emerging role, urology perspective June 6, 2013

Slide Lecture: Therapeutic benefit of baseline PSA: Lower baseline PSA is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial June 6, 2013

Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy - Abstract June 5, 2013

Comparison of oncologic outcomes after radical prostatectomy in men diagnosed with prostate cancer with PSA levels below and above 4 ng/mL - Abstract June 5, 2013

Adjuvant radiotherapy or early salvage radiotherapy in pT3R0 or pT3R1 prostate cancer - Abstract June 5, 2013

Novel imaging techniques reshape the landscape in high-risk prostate cancers - Abstract June 5, 2013

Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer - Abstract June 5, 2013

Page 1166 of 1450